A recent study indicates that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a leading medical journal demonstrates that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"People buying such treatments must be informed of the risk of fast weight regain when the medication concludes," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment mass in about 18 months.
Comparing Approaches
The research, which examined 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with conventional dieting.
The team emphasize that people who lose weight through diet and exercise generally see a slower creep back—approximately 0.1 kg a month—once they finish.
Understanding the Fast Regain
Doctors propose the way of the jabs accounts for the amplified weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means hunger is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
Health authorities recommend the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, given the high risk of weight regain, the therapy might need to be long-term.
This opinion is echoed by drug manufacturers, who say that the findings "underscore the long-term character of obesity," comparing it to managing diseases like high blood pressure.
User Testimonies
Users who have stopped the jabs report a intense return of hunger.
"I experienced a switch activating and you're instantly ravenous," said one woman.
This difficulty is exacerbated if users have not established sustainable lifestyle or habit changes during treatment.
Significant Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is greater among women than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a standalone fix and long-term success hinges on combined behavioural changes.
